MarketCapExport financials
Calithera Biosciences (CALA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Calithera Biosciences Balance Sheet 2022-2011 | CALA
Brief overview of Calithera Biosciences's balance sheet strength
The review uses the five latest available annual reports between 2018 and 2022.
Assets fell from $142.7 million to $28.7 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, -48.3% versus -79.9%. Debt-service capacity deserves attention.
Equity accounts for 71.1% of assets. Against the initial 88.8%, the capital position looks resilient.
Net debt moved below zero to -$23.8 million, reflecting surplus cash over debt.
The cash reserve occupies 88.8% of the balance sheet, previously 35.8%. It is one marker of short-term resilience.
The balance sheet carries negative retained earnings of -$512.6 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
The balance sheet gives no single signal for Calithera Biosciences: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet Calithera Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-23.8 M | -56.5 M | -100 M | -52.2 M | -51.1 M | -48.5 M | -10.6 M | -6.1 M | -102 M | -33.8 M | -2.2 M | - |
Long Term Debt |
136 K | 1.67 M | 4.82 M | 6.72 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.53 M | 1.37 M | 1.9 M | 1.48 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 4.82 M | 6.72 M | 1.13 M | 3.12 M | 437 K | 129 K | 283 K | 54.3 M | 10.7 M | - |
Total Current Liabilities |
7.39 M | 14 M | 18.4 M | 19.6 M | 14.9 M | 39 M | 4.45 M | 3.83 M | 4.12 M | 1.34 M | - | - |
Total Liabilities |
8.28 M | 15.7 M | 23.2 M | 26.3 M | 16 M | 42.1 M | 4.89 M | 3.96 M | 4.4 M | 1.38 M | 11.6 M | - |
Deferred Revenue |
- | - | - | 1.55 M | 2.47 M | 29 M | - | - | - | - | - | - |
Retained Earnings |
-513 M | -491 M | -376 M | -286 M | -196 M | -150 M | -123 M | -84.5 M | -51.9 M | -30.1 M | -17.8 M | - |
Total Assets |
28.7 M | 64.8 M | 126 M | 169 M | 143 M | 192 M | 54.8 M | 75.8 M | 105 M | 34.8 M | 3.06 M | - |
Cash and Cash Equivalents |
25.5 M | 59.5 M | 107 M | 60.4 M | 51.1 M | 48.5 M | 10.6 M | 6.1 M | 102 M | 33.8 M | 2.2 M | - |
Book Value |
20.4 M | 49.1 M | 102 M | 142 M | 127 M | 150 M | 49.9 M | 71.8 M | 100 M | 33.5 M | -8.57 M | - |
Total Shareholders Equity |
20.4 M | 8.38 M | 102 M | 142 M | 127 M | 150 M | 49.9 M | 71.8 M | 100 M | -20.8 M | -8.57 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 533 K | 917 K | 1.3 M | 1.67 M | 2.02 M | 2.37 M | 2.71 M | 4.82 M | 5.31 M | 5.79 M | 6.26 M | 6.72 M | 7.16 M | 7.58 M | 7.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 292 K | - | - | 31 K | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 10.7 M | 10.3 M | 12.7 M | 15.7 M | 15.6 M | 14.8 M | 16.5 M | 23.2 M | 25.1 M | 21.6 M | 22 M | 26.3 M | 25.7 M | 27 M | 25.9 M | 16 M | 11.8 M | 11.8 M | 30.7 M | 42.1 M | 47.5 M | 51.6 M | 58.2 M | 4.89 M | 5.11 M | 5.01 M | 4.29 M | 3.96 M | 5.94 M | 4.43 M | 3.77 M | 4.4 M | 4.41 M | 4.4 M | 4.4 M | 1.38 M | 1.38 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29 M | 29 M | 17.1 M | 29 M | 29 M | 29 M | 29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -506 M | -496 M | -505 M | -491 M | -422 M | -411 M | -397 M | -376 M | -354 M | -331 M | -311 M | -286 M | -264 M | -244 M | -220 M | -196 M | -177 M | -158 M | -155 M | -150 M | -139 M | -133 M | -128 M | -123 M | -113 M | -104 M | -94.1 M | -84.5 M | -76.4 M | -67.5 M | -59.7 M | -51.9 M | -45 M | -51.9 M | -51.9 M | -30.1 M | -30.1 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 37.1 M | 45.6 M | 50.2 M | 64.8 M | 90 M | 97.9 M | 111 M | 126 M | 148 M | 165 M | 150 M | 169 M | 146 M | 166 M | 132 M | 143 M | 148 M | 159 M | 179 M | 192 M | 206 M | 214 M | 224 M | 54.8 M | 58.9 M | 63.2 M | 71.6 M | 75.8 M | 84.5 M | 90.7 M | 96.9 M | 105 M | 39.6 M | 105 M | 105 M | 34.8 M | 34.8 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 34.1 M | 41.8 M | 44.7 M | 59.5 M | 84.5 M | 92.2 M | 101 M | 107 M | 121 M | 115 M | 40.5 M | 60.4 M | 21.7 M | 76.8 M | 40.6 M | 51.1 M | 61.1 M | 55.9 M | 54.8 M | 48.5 M | 39.4 M | 58 M | 89.1 M | 10.6 M | 11.6 M | 7.33 M | 12.2 M | 6.1 M | 8.43 M | 11.3 M | 73.9 M | 102 M | 34.9 M | 102 M | 102 M | 33.8 M | 33.8 M | - | - | 2.2 M | - | - | - | 3.28 M | - | - | - |
Book Value |
- | 26.4 M | 35.3 M | 37.6 M | 49.1 M | 74.4 M | 83 M | 94.2 M | 102 M | 123 M | 143 M | 128 M | 142 M | 121 M | 139 M | 106 M | 127 M | 136 M | 147 M | 148 M | 150 M | 158 M | 162 M | 166 M | 49.9 M | 53.8 M | 58.2 M | 67.3 M | 71.8 M | 78.6 M | 86.3 M | 93.1 M | 100 M | 35.2 M | 100 M | 100 M | 33.5 M | 33.5 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | 26.4 M | 35.3 M | -3.14 M | 8.38 M | 74.4 M | 83 M | 94.2 M | 102 M | 123 M | 143 M | 128 M | 142 M | 121 M | 139 M | 106 M | 127 M | 136 M | 147 M | 148 M | 150 M | 158 M | 162 M | 166 M | 49.9 M | 53.8 M | 58.2 M | 67.3 M | 71.8 M | 78.6 M | 86.3 M | 93.1 M | 100 M | -35 M | 100 M | 100 M | -20.8 M | -20.8 M | - | - | -8.57 M | - | - | - | -3.56 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Calithera Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
